Cargando…

Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage

In cancer, overactivation of poly (ADPribose) polymerases (PARP) plays a relevant role in DNA repair. We hypothesized that treatment with the PARP inhibitor rucaparib may reduce tumor burden via several biological mechanisms (apoptosis and oxidative stress) in mice. In lung tumors (LP07 lung adenoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Peiró, Maria, Valentí-Serra, Paula, León-González, Blanca, Ampurdanés, Coral, Duran, Xavier, Yélamos, José, Barreiro, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916668/ https://www.ncbi.nlm.nih.gov/pubmed/36768904 http://dx.doi.org/10.3390/ijms24032580

Ejemplares similares

Attenuation of Muscle Damage, Structural Abnormalities, and Physical Activity in Respiratory and Limb Muscles following Treatment with Rucaparib in Lung Cancer Cachexia Mice
por: Pérez-Peiró, Maria, et al.
Publicado: (2022)

Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD
por: Tang, Jun, et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
por: Curtin, Nicola J
Publicado: (2020)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
por: Saravi, Sayeh, et al.
Publicado: (2021)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
por: Zhang, Qilin, et al.
Publicado: (2023)

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity
por: Wang, Xian, et al.
Publicado: (2018)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

A cyanide-catalyzed imino-Stetter reaction enables the concise total syntheses of rucaparib
por: Park, Jinjae, et al.
Publicado: (2022)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
por: Tookman, Laura, et al.
Publicado: (2020)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Curcumin and Resveratrol Improve Muscle Function and Structure through Attenuation of Proteolytic Markers in Experimental Cancer-Induced Cachexia
por: Penedo-Vázquez, Antonio, et al.
Publicado: (2021)

Iron Depletion in Systemic and Muscle Compartments Defines a Specific Phenotype of Severe COPD in Female and Male Patients: Implications in Exercise Tolerance
por: Pérez-Peiró, Maria, et al.
Publicado: (2022)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
por: Wilson, Richard H, et al.
Publicado: (2017)

Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
por: Yoshida, Reiko, et al.
Publicado: (2022)

Correction: Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Polyphenols Attenuate Highly-Glycosylated Haemoglobin-Induced Damage in Human Peritoneal Mesothelial Cells
por: Sánchez-Rodríguez, Carolina, et al.
Publicado: (2020)

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
por: Lorusso, Domenica, et al.
Publicado: (2020)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9drj1e86l1s5uoj32082com5ru